Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow.

Arterioscler Thromb Vasc Biol

From the Biomedical Engineering, School of Medicine (J.Z.-R., A.I., C.P.W., E.I.T., A.G., O.J.T.M.) and Division of Hematology (A.G., O.J.T.M.), Oregon Health & Science University, Portland; Pathology and Medicine, School of Medicine, Vanderbilt University, Nashville, TN (D.G.); Aronora Inc., Portla

Published: March 2016


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Coagulation factor XI (FXI) has been shown to contribute to thrombus formation on collagen or tissue factor-coated surfaces in vitro and in vivo by enhancing thrombin generation. Whether the role of the intrinsic pathway of coagulation is restricted to the local site of thrombus formation is unknown. This study was aimed to determine whether FXI could promote both proximal and distal platelet activation and aggregate formation in the bloodstream.

Approach And Results: Pharmacological blockade of FXI activation or thrombin activity in blood did not affect local platelet adhesion, yet reduced local platelet aggregation, thrombin localization, and fibrin formation on immobilized collagen and tissue factor under shear flow, ex vivo. Downstream of the thrombus formed on immobilized collagen or collagen and 10 pmol/L tissue factor, platelet CD62P expression, microaggregate formation, and progressive platelet consumption were significantly reduced in the presence of FXI function-blocking antibodies or a thrombin inhibitor in a shear rate- and time-dependent manner. In a non-human primate model of thrombus formation, we found that inhibition of FXI reduced single platelet consumption in the bloodstream distal to a site of thrombus formation.

Conclusions: This study demonstrates that the FXI-thrombin axis contributes to distal platelet activation and procoagulant microaggregate formation in the blood flow downstream of the site of thrombus formation. Our data highlight FXI as a novel therapeutic target for inhibiting distal platelet consumption without affecting proximal platelet adhesion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767639PMC
http://dx.doi.org/10.1161/ATVBAHA.115.307034DOI Listing

Publication Analysis

Top Keywords

distal platelet
16
platelet consumption
16
thrombus formation
16
platelet activation
12
site thrombus
12
platelet
11
coagulation factor
8
single platelet
8
consumption bloodstream
8
shear flow
8

Similar Publications

Early angiographic response to Pipeline Vantage flow diverter embolization of intracranial carotid aneurysms.

J Neurointerv Surg

August 2025

Department of Neurosurgery, Cerebrovascular and Endovascular Division, Tufts Medical Center, Boston, Massachusetts, USA

Background: The Pipeline Vantage 027 flow diverter became available a year ago in the United States. We report an observational study of its safety and early angiographic response in the treatment of internal carotid artery (ICA) aneurysms.

Methods: All patients treated with the Vantage 027 for ICA aneurysms from April to November 2024 at a single center were included.

View Article and Find Full Text PDF

Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.

View Article and Find Full Text PDF

: The TOPAZ-1 phase III trial reported a survival benefit of using durvalumab, an anti-programmed death ligand 1 (anti-PD-L1) antibody, in combination with gemcitabine and cisplatin (GCD) treatment in patients with advanced biliary tract cancer. This retrospective study investigated the efficacy and safety of GCD treatment for advanced biliary tract cancer in real-world conditions. : The study subjects were 52 patients with biliary tract cancer who received GCD therapy between January 2023 and May 2024.

View Article and Find Full Text PDF

Background: Ischemia/reperfusion injury after lung transplantation is a significant cause of morbidity. In the realm of ex vivo lung perfusion (EVLP), inflammation, edema formation, and reduced compliance have limited the durability of EVLP. Previous evidence has suggested that platelet activation and thrombosis may play a role in both conditions.

View Article and Find Full Text PDF

Purpose: This overview summarized different interventions that were performed for minimizing periodontal defects distal to the mandibular second molar and improve hard and soft tissue healing after third molar surgery.

Methods: Literature search was conducted in the following 9 databases: Medline (via Pubmed), ScienceDirect, Scopus, Virtual Health Library, Wiley Online Library, Web of Science, ProQuest Dissertations and Theses Global and Google Scholar. Systematic reviews with or without meta-analysis investigating the effect of different interventions on soft and hard tissue healing after third molar surgery were considered.

View Article and Find Full Text PDF